VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to ...

D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT. All of our product candidates are in clinical or preclinical development and have not yet ...

Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.

Brandi Glanville, 52, still seeks answers after two years of unexplained facial swelling, sharing graphic health updates with fans since 2023.

The Heart Failure Drugs Market is poised for a transformative decade between 2025 and 2035. As heart failure continues to ...

Vantage Biosciences, a clinical stage biotechnology company advancing innovative therapies for diabetic eye diseases, today announced that the first patient has been successfully dosed in its Phase 2 ...

A post-hoc analysis of the DUPLEX trial shows significantly greater improvements in proteinuria-related outcomes vs irbesartan for tough-to-treat FSGS.

Former Beltrami jail nurse Michelle Skroch made her first appearance in court Friday. She’s charged with criminal neglect and ...

Learn more about whether Alvotech or Ultragenyx Pharmaceutical Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Alvotech or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

There are many other types of rashes with a wide variety of causes. Treatment for a rash requires the correct diagnosis and can include medication and avoiding potential triggers.  Easily ...